Proacta Adds $35M In Series B

San Diego-based Proacta, a biotechnology firm developing cancer drugs, said today that it has added $35M in a Series B financing. The new funding will be used to take its lead compound into the next phase of clinical development, as well as to go towards discovery and development of additional compounds. The round was led by Clarus Ventures, and also included Delphi Ventures, Alta Partners, GBS Venture Partners (Australia), No 8 Ventures and Endeavour iCap, Genentech and Roche. More information »